Immunotherapy with histamine dihydrochloride and low‐dose interleukin‐2 favors sustained lymphocyte recovery in acute myeloid leukemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|94|3|279-280

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.94, Iss.3, 2015-03, pp. : 279-280

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunotherapy in acute myeloid leukemia

By  

CANCER, Vol. 121, Iss. 16, 2015-08 ,pp. : 2689-2704

John Wiley & Sons Inc

Access to resources Recommend Favorite

Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

By  

CANCER, Vol. 121, Iss. 14, 2015-07 ,pp. : 2375-2382

John Wiley & Sons Inc

Access to resources Recommend Favorite

Five-Year Survival Results of Subcutaneous Low-Dose Immunotherapy with Interleukin-2 Alone in Metastatic Renal Cell Cancer Patients

By  

Urologia Internationalis, Vol. 64, Iss. 1, 2000-04 ,pp. : 3-8

Karger

Access to resources Recommend Favorite

Posttreatment interleukin‐2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials?

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 940-941

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sustained Response to Low-Dose Imatinib Mesylate in a Patient with Chronic Myelomonocytic Leukemia with t(5;12)(q33;p13)

By  

Acta Haematologica, Vol. 119, Iss. 1, 2008-02 ,pp. : 57-59

Karger

Access to resources Recommend Favorite